Key Insights• The Saudi Arabian radiotherapy market operates within a rapidly evolving healthcare system, with significant government investment in advanced cancer care infrastructure aligned with Vision 2030. Cancer rates in the GCC region are projected to rise by over 140% between 2020 and 2040, driving sustained demand for radiation oncology services .• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, with linear accelerators forming the backbone of treatment delivery. Varian Medical Systems holds an estimated 40–50% of the installed base, followed by Elekta at 30–40% . IMRT and IGRT techniques have been progressively integrated across healthcare facilities nationwide .• Radiotherapy systems and equipment represent the largest offering segment, with the market entirely import-dependent. The Kingdom has no domestic teletherapy machine manufacturing capability, with equipment sourced from the United States, Europe, and Japan . A standard single-energy linear accelerator with IGRT capabilities typically carries an equipment price of USD 2.0–3.5 million .• Hospitals and integrated cancer centres are the largest end-user segment, though disparities exist between public and private sectors.

A 2024 survey of 17 radiotherapy centres found public and mixed facilities treated a mean of 911 and 2,141 patients annually respectively, compared with 254 patients at private centres . The Central Region, anchored by Riyadh, dominates the market due to the concentration of healthcare infrastructure .• Regulatory oversight is provided by the Saudi Food and Drug Authority, which mandates technical and clinical specification approval for radioactive medical materials before licensing by the Nuclear and Radiological Regulatory Authority . The Kingdom has emerged as a pioneer in advanced cancer care in the region, with the Saudi Proton Therapy Centre in Riyadh becoming fully operational in December 2023 as the first and only proton beam therapy facility in the Middle East .Market Outlook• According to the research report, "Saudi Arabia Radiotherapy Market Overview, 2031," published by Actual Market Research, the Saudi Arabia Radiotherapy market is anticipated to add to more than USD 20 Million by 2026–31. This growth reflects sustained government investment through Vision 2030, expansion of advanced treatment capabilities, and increasing cancer incidence across the Kingdom.• The market is expected to benefit from continued investment in radiotherapy infrastructure. The Saudi Proton Therapy Centre at King Fahd Medical City represents one of the largest health sector projects, established on an area of 4,000 square metres at a cost exceeding SR 924 million (approximately USD 246 million) . The centre aims to treat about 1,700 patients annually with precise proton beam therapy for complex oncologic cases, eliminating the need for patients to travel abroad for treatment .• Technology adoption is accelerating through the integration of advanced radiotherapy systems. Varian installed the first Halcyon system in Saudi Arabia in April 2024 at the Batik-X radiation therapy centre in Riyadh, in partnership with BaraSeen Medical Company .

The Kingdom is also pioneering in cancer radiopharmaceuticals, with King Faisal Specialist Hospital and Research Centre locally producing essential radionuclides such as iodine-123 and gallium-67, reducing reliance on imports .• The market is also influenced by workforce and access challenges. A 2024 study published in Frontiers in Oncology found that public and private sector disparities may undermine equitable access to radiotherapy services, with waiting times for radical treatment in public centres requiring policy attention . Training gaps across many centres suggest the need for coordinated national continuing professional development programmes to support safe implementation of advanced technologies .• Long-term growth is supported by sustained policy commitment. Johns Hopkins Aramco Healthcare unveiled plans for an Oncology Center of Excellence in Riyadh in October 2025, specialising in breast, colorectal, and prostate cancers . Strategic partnerships between the Ministry of Investment, KFSH&RC, and international pharmaceutical companies are advancing integrated cancer treatment approaches combining cell therapy and radiotherapy .Market DynamicsDriver: Vision 2030 Healthcare Transformation and Infrastructure InvestmentThe primary driver of the Saudi Arabian radiotherapy market is the Kingdom's comprehensive healthcare transformation under Vision 2030. The Health Sector Transformation Programme is restructuring the Ministry of Health from a provider-regulator into a regulator and strategist, with clinical delivery devolving into regional Health Clusters and Centres of Excellence .

This framework has catalysed substantial investment in radiotherapy infrastructure, exemplified by the Saudi Proton Therapy Centre the first and only proton beam therapy facility in the Middle East which became fully operational in December 2023 at a cost exceeding SR 924 million . The centre provides highly targeted radiation therapy particularly effective for tumours in sensitive areas such as the brain, spine, and head and neck, as well as in paediatric oncology . The Kingdom's commitment to healthcare excellence, supported by strategic partnerships with global institutions like Johns Hopkins Medicine, has further bolstered its reputation as a regional healthcare hub, attracting patients seeking specialised treatments and stimulating market demand for radiotherapy services .Challenge: Import Dependency and Workforce ConstraintsA significant challenge facing the Saudi Arabian radiotherapy market is the complete import dependency for teletherapy machines and the structural workforce shortages that constrain service delivery. No Saudi-based manufacturer of teletherapy machines exists, and technological and regulatory barriers to entry remain prohibitive for local production . The Kingdom relies entirely on global OEM supply chains, with typical order-to-delivery lead times of 6–9 months for standard linear accelerators . Additionally, a 2024 survey of 17 radiotherapy centres found that public and mixed facilities treated significantly higher patient volumes (mean of 911 and 2,141 patients/year respectively) compared with private centres (mean of 254 patients/year), indicating capacity and access disparities .

The study identified that structural factors including workforce capacity, equipment allocation, training infrastructure, and procurement processes may undermine equitable access to radiotherapy services across the Kingdom . Training gaps across many centres suggest the need for coordinated national continuing professional development programmes rather than relying solely on vendor-based education .Trend: Proton Therapy Expansion and Advanced Technology AdoptionA major trend shaping the Saudi Arabian radiotherapy market is the expansion of proton therapy capabilities and the adoption of advanced treatment technologies. The Saudi Proton Therapy Centre, the first facility of its kind in the Middle East, is fully operational and targeting to treat about 1,700 patients annually . The centre features a cyclotron, beam transport system, rotating gantry, five treatment rooms with control rooms, CT simulation room, and radiation planning systems . Proton therapy is particularly indicated when tumours are adjacent to vital organs, when radiation dose exceeds safe levels for organs, and for re-irradiation cases demonstrating clear applications in eye, spinal cord, brain, skull base, liver, paediatric, and sinus tumours . Beyond proton therapy, the Kingdom is advancing integrated cancer treatment approaches.

In May 2025, ImmunityBio signed a Memorandum of Understanding with the Ministry of Investment, KFSH&RC, and KAIMRC to launch the FDA-approved "Cancer BioShield" immunotherapy platform in the Middle East, integrating cell therapy and radiotherapy . KFSH&RC is also pioneering CAR-T cell therapy and CRISPR gene editing for cancer treatment, positioning the Kingdom at the forefront of oncology innovation .Policies• The Saudi Food and Drug Authority requires technical and clinical specification approval for radioactive medical materials before licensing by the Nuclear and Radiological Regulatory Authority, under Royal Decree No. M/54 (1442 AH) . The approval process for importing radioactive medical materials requires establishment accounts in the electronic MRMR system .• The Nuclear and Radiological Regulatory Authority issues licences for activities related to the use of radioactive medical materials. Facilities must obtain necessary licences for beneficiary, transporter, and supplier entities before SFDA approval can be granted .• The Health Sector Transformation Programme under Vision 2030 is restructuring the Ministry of Health into a regulator and strategist, with clinical delivery devolving into regional Health Clusters and Centres of Excellence . The programme names tertiary cancer care as a priority vertical .• Saudi Arabia's Health Sector Transformation Programme is expanding the universe of specialty drugs that receive formal SFDA registration while simultaneously increasing diagnostic capacity in oncology genomics .

This creates sustained demand for radiotherapy services and associated equipment.• The Saudi Proton Therapy Centre at King Fahd Medical City represents one of the largest health sector projects, established on an area of 4,000 square metres at a cost exceeding SR 924 million, and is the first and only proton beam therapy facility in the Middle East .• Johns Hopkins Aramco Healthcare, a joint venture between Saudi Aramco and Johns Hopkins Medicine, unveiled plans for an Oncology Center of Excellence in Riyadh in October 2025, specialising in breast, colorectal, and prostate cancers .Segment AnalysisSaudi Arabia Radiotherapy Market By Therapy Type• External Beam Radiotherapy (EBRT): This is the largest therapy segment, supported by an installed base of linear accelerators across public, private, and military healthcare facilities. Varian Medical Systems holds an estimated 40–50% of the installed base, while Elekta accounts for approximately 30–40% . EBRT is versatile and effective, offering precise targeting of tumours with minimal side effects through advanced techniques including IMRT and IGRT . The availability of skilled radiation oncologists, medical physicists, and technologists trained in EBRT further supports its widespread adoption .• Internal / Brachytherapy: This segment remains clinically established, particularly for gynaecological cancers including cervical cancer. The 2024 survey of 17 radiotherapy centres found that public facilities had a mean of 0.67 brachytherapy units, while mixed facilities had a mean of 1 unit, and private facilities had none . This indicates infrastructure concentration and potential access disparities.• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies.

KFSH&RC is leading innovation in cancer radiopharmaceuticals by locally producing essential radionuclides such as iodine-123 and gallium-67 . The SFDA has established specific requirements for importing radioactive medical materials, including technical and clinical specification approval .Saudi Arabia Radiotherapy Market By Offering• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by high capital costs and sustained government investment. Saudi Arabia is completely import-dependent for teletherapy machines, with no domestic manufacturing capability . A standard single-energy linear accelerator with IGRT capabilities typically costs USD 2.0–3.5 million, while dual-energy systems with stereotactic features command USD 3.5–5.0 million . Compact proton therapy systems can exceed USD 15–25 million inclusive of building-integrated shielding and installation . Total project costs, including bunker construction and shielding, add 40–60% to the base equipment price .• Software & Services: This is the fastest-growing segment, reflecting increasing digitalisation of radiation oncology and the need for lifecycle management.

Service contract pricing follows a standard range of 10–15% of equipment value per year, with escalation clauses tied to local labour costs and parts availability . Competitive dynamics centre on clinical workflow integration, uptime guarantees, and training support rather than price alone . Regional distribution partners, such as Al-Mofida Medical Equipment Co., handle logistics, customs clearance, and after-sales service .Saudi Arabia Radiotherapy Market By Application• Breast Cancer: This is the largest application segment, with breast cancer one of the most prevalent and treated cancers in Saudi Arabia . The proactive approach of the Saudi healthcare system in promoting breast cancer awareness and screening programmes has led to earlier detection and diagnosis, resulting in more effective treatment outcomes with radiotherapy playing a pivotal role . The JHAH Oncology Center of Excellence specialises in breast cancer treatment .• Prostate Cancer: A significant application area, with JHAH's Oncology Center of Excellence specialising in prostate cancer alongside breast and colorectal cancers . EBRT is widely utilised for prostate cancer treatment across the Kingdom.• Colorectal Cancer: A significant application area, with JHAH's Oncology Center of Excellence specialising in colorectal cancer .

Radiotherapy plays a role in neoadjuvant and adjuvant treatment.• Lung Cancer: A growing application segment, with advanced radiotherapy techniques being adopted across Saudi healthcare facilities . The Saudi Proton Therapy Centre is equipped to treat lung cancer and other complex cases .• Head & Neck Cancer: This is a critical application requiring highly conformal radiation delivery. Proton therapy offers significant advantages for head and neck cancers by reducing dose to adjacent critical structures .• Paediatric Cancers: Proton therapy is especially effective for paediatric cancers, as it reduces long-term side effects and protects healthy tissue during child development . The Saudi Proton Therapy Centre is equipped for paediatric oncology .• Central Nervous System / Brain: A significant application area, with proton therapy particularly beneficial for brain tumours and CNS tumours .Saudi Arabia Radiotherapy Market By End User• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, operating within the public healthcare system. A 2024 survey found public facilities operated a mean of 2.1 LINACs and treated a mean of 911 patients annually . Major centres include King Faisal Specialist Hospital and Research Centre, King Fahd Medical City (Saudi Proton Therapy Centre), and Johns Hopkins Aramco Healthcare .

These institutions manage the most complex equipment fleets and are the primary beneficiaries of government investment programmes.• Standalone Radiotherapy Centres: This segment includes private and mixed facilities. Private facilities operated a mean of 1.2 LINACs and treated a mean of 254 patients annually, while mixed facilities operated a mean of 5 LINACs and treated a mean of 2,141 patients annually . The Batik-X radiation therapy centre in Riyadh, which received the first Halcyon system in Saudi Arabia, represents private sector investment .• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in clinical research and technology validation. KFSH&RC is leading innovation in CAR-T cell therapy, CRISPR gene editing, and radiopharmaceuticals . The collaboration between RaySearch Laboratories and C-RAD in May 2024 to develop innovative radiotherapy solutions demonstrates the research focus in the Kingdom .Saudi Arabia Radiotherapy Market Economics• Equipment procurement in Saudi Arabia is entirely import-based, with no domestic manufacturing capability for teletherapy machines . Standard single-energy linear accelerators with IGRT capabilities range from USD 2.0–3.5 million; dual-energy systems with stereotactic features range from USD 3.5–5.0 million; stereotactic radiosurgery platforms range from USD 4.5–7.0 million; and compact proton therapy systems can exceed USD 15–25 million inclusive of installation .• Total project costs, including bunker construction, shielding, treatment-planning software, and patient positioning systems, add 40–60% to the base equipment price .

Tariff treatment under the GCC Customs Union generally applies a 0–5% duty rate .• Service contract pricing follows a standard range of 10–15% of equipment value per year, with escalation clauses tied to local labour costs and parts availability . Competitive dynamics centre on clinical workflow integration, uptime guarantees, and training support .• The Saudi Proton Therapy Centre represents one of the largest health sector investments at a cost exceeding SR 924 million (approximately USD 246 million) . The centre aims to treat about 1,700 patients annually, eliminating the need for patients to travel abroad for proton therapy .• Workforce constraints present economic challenges. The 2024 survey found that public and private sector disparities may undermine equitable access to radiotherapy services, with waiting times for radical treatment in public centres requiring policy attention . Training gaps across many centres suggest the need for coordinated national CPD programmes .• Cost drivers include global supply-chain concentration among three dominant linear accelerator manufacturers, currency fluctuations, and input-cost escalation for high-power microwave components, precision-machined gantry assemblies, and semiconductor-based imaging detectors .Market Outlook by Infrastructure, Investment and Industry Development• The Saudi Proton Therapy Centre at King Fahd Medical City, the first and only proton beam therapy facility in the Middle East, is fully operational. Established on 4,000 square metres at a cost exceeding SR 924 million, the centre features a cyclotron, beam transport system, rotating gantry, five treatment rooms, CT simulation, and radiation planning systems .• Johns Hopkins Aramco Healthcare unveiled plans for an Oncology Center of Excellence in Riyadh in October 2025, specialising in breast, colorectal, and prostate cancers .

The centre will provide comprehensive, patient-centric care and represents the Kingdom's commitment to world-class oncology services.• King Faisal Specialist Hospital and Research Centre is leading innovation in cancer radiopharmaceuticals by locally producing essential radionuclides, reducing reliance on imports . KFSH&RC is also pioneering CAR-T cell therapy and CRISPR gene editing for cancer treatment .• Technology modernisation is advancing through partnerships between global and local companies. Varian installed the first Halcyon system in Saudi Arabia at the Batik-X radiation therapy centre in Riyadh in April 2024 . RaySearch Laboratories and C-RAD signed a collaboration agreement in May 2024 to develop innovative radiotherapy solutions .• Strategic partnerships are expanding treatment options. In May 2025, ImmunityBio signed a MoU with MISA, KFSH&RC, and KAIMRC to launch the "Cancer BioShield" immunotherapy platform in the Middle East, integrating cell therapy and radiotherapy . In July 2025, CEL-SCI Corporation announced a partnership for commercialisation of Multikine immunotherapy for head and neck cancer .• Workforce development is a critical priority.

A 2024 study identified that training gaps across many centres suggest the need for coordinated national continuing professional development programmes to support safe implementation of advanced technologies . The study's findings provide timely evidence to inform outsourcing initiatives, strategic planning, policy development, and investment decisions .• The long-term outlook remains positive as cancer rates in the GCC region are projected to rise by over 140% between 2020 and 2040 . Sustained government investment through Vision 2030, the expansion of proton therapy capabilities, and strategic partnerships with global institutions position Saudi Arabia as a regional hub for specialised cancer care .Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Radiotherapy Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Therapy Type• External Beam Radiotherapy (EBRT)• Internal / Brachytherapy• Systemic RadiotherapyBy Offering• Radiotherapy Systems/Equipment• Software & ServicesBy Application• Breast Cancer• Prostate Cancer• Lung Cancer• Head & Neck Cancer• Central Nervous System / Brain• Gastro-intestinal• Other ApplicationsBy End User• Hospitals & Integrated Cancer Centers• Standalone Radiotherapy Centers• Academic/Research Institutions• Other Healthcare Facilities.